Hershberger, Courtney
Mariam, Arshiya
Pantalone, Kevin M.
Buse, John B.
Motsinger-Reif, Alison A.
Rotroff, Daniel M.
Funding for this research was provided by:
Cleveland Clinic Center for Quantitative Metabolic Research
National Center for Advancing Translational Sciences (UM1TR004406)
National Institute of Environmental Health Sciences
Article History
Received: 30 April 2024
Accepted: 12 June 2024
First Online: 22 June 2024
Declarations
:
: D.M.R and K.M.P have received funding from Novo Nordisk and Bayer. K.M.P has also obtained research support from and Merck and Twin Health as well as speaker honoraria from AstraZeneca, Corcept Therapeutics, Merck, and Novo Nordisk, and consulting honoraria from AstraZeneca, Bayer, Corcept Therapeutics, Diasome, Eli Lilly, Merck, Novo Nordisk, and Sanofi. D.M.R has an equity stake in Clarified Precision Medicine and Genovation Health, LLC. JBB’s employer receives contracted consulting fees and travel support for contracted activities by Novo Nordisk; he receives grant support by Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; he is a consultant Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mellitus Health, Metsera, Moderna, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, and Vertex; he has provided expert witness testimony for Medtronic MiniMed; he has stock options in Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. D.M.R., K.M.P, and A.M have intellectual property related to predicting diabetes subtypes. No other conflicts of interest pertinent to this article were reported.